Committed to developing a device that will eradicate maternal death caused by postpartum hemorrhage (PPH)

InPress Technologies is a medical device company working toward a solution to postpartum hemorrhage (PPH,) the number one cause of maternal death. Our single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. With our simple, non-invasive device, we are devoted to improving the lives of women around the world.

InPress Technologies is a company-in-residence at the Fogarty Institute for Innovation (FII,) in Mountain View CA. FII is a catalyst for medical device innovation and provides intellectual and physical resources to early-stage innovators whose ideas have significant technical merit and a high potential of improving the lives of people around the world. In July 2014, InPress was the recipient of the Lefteroff Innovator Award, which directly funds projects for promising new innovators working on pre-screened medical ideas. The Lefteroff Fund was developed to recognize Tracy Lefteroff for his legacy of commitment and dedication to entrepreneurship, investment and innovation in the life sciences.

InPress Technologies traces its history to Cal Poly (California Polytechnic State University) in San Luis Obispo, CA, where two biomedical engineers conceived our innovative approach to postpartum hemorrhage. Over the next couple of years, the team received extensive support from Innovation Quest, the San Luis Obispo HotHouse Accelerator, and the Cal Poly Small Business Development Center. The encouragement of these organizations helped the founders synthesize their idea further, conduct initial analyses, and outline a path to bring the product to market.

Partners and Mentors

  • Fogarty Institute for Innovation Company in Residence
  • SLO HotHouse Incubator Company
  • Schox Patent Group
  • Safe Motherhood Program at UCSF:Bixby Center for Global Reproductive Health
  • The Cal Poly Center for Innovation & Entrepreneurship

The InPress device aims to quickly and effectively counter the leading cause of postpartum hemorrhage (PPH)

Postpartum hemorrhage (PPH) is excessive bleeding in a mother after childbirth. PPH is the leading cause of perinatal maternal death around the world—it is estimated that one woman dies from PPH every four minutes.

Clinically, 80% of the instances of PPH are caused by the failure of the uterus to contract after childbirth. This condition, known as uterine atony, leaves the blood vessels fully dilated and brings about unobstructed bleeding.

The InPress facilitates the body's natural mechanism for healing to address postpartum hemorrhage, without pharmaceuticals, hysterectomy, or other invasive surgical procedures. As opposed to merely treating the symptoms of PPH, the InPress is designed to stop bleeding by stimulating uterine contraction. When the InPress is inserted into a uterus upon childbirth, its proprietary mechanism is intended to stimulate the body's natural post-delivery response by gently contracting the uterus back to the right postpartum size.

The InPress will work quickly and effectively. It can dramatically reduce the cost of healthcare during childbirth and substantially reduce the risk of loss of life. We foresee the InPress becoming a part of the standard procedure for childbirth around the world. Our vision is to make the InPress affordable and accessible in developed and developing countries thus helping save the lives of women around the world.

  • "The InPress technology has the potential to change the way postpartum hemorrhage is treated and save many lives."
    Suellen Miller, Director of Safe Motherhood Program
  • "The InPress device is uniquely designed to work in concert with normal uterine mechanisms to prevent or stop PPH."
    Jan Segnitz, MD, OB/GYN
  • "Given the physiology of the uterus, the InPress
    device is the only approach that makes sense."
    Dr. Rebekah Sharp, practicing OB/GYN, Michigan

Vision. Inspiration. Experience. Impact.

Updates

After years of development, collaboration with top OBGYNs, diligent bench testing, risk analysis, and after an initial production run, InPress was ready to deploy the device in its first clinical trial. This initial study, with Ethics Committee oversight is now nearing completion. InPress Technologies is excited to share that the preliminary clinical study results of the InPress device have been successful.

Note: No regulatory approvals or clearances have yet been issued by Regulation Agencies for the InPress device to date.

Inpress is ISO 13485 Certified

InPress Technologies has developed the necessary engineering controls to ensure consistent product quality. The InPress quality system has earned the company this internationally recognized medical device certification of ISO 13485.

We aim to treat postpartum hemorrhage (PPH) quickly and effectively.